Kory James Wentworth - Dec 2, 2022 Form 4 Insider Report for Entrada Therapeutics, Inc. (TRDA)

Role
Chief Financial Officer
Signature
/s/ Jared Cohen, as Attorney-in-Fact
Stock symbol
TRDA
Transactions as of
Dec 2, 2022
Transactions value $
-$50,028
Form type
4
Date filed
12/6/2022, 04:02 PM
Previous filing
Nov 18, 2022
Next filing
Dec 12, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TRDA Common Stock Options Exercise $6.11K +2.91K +17.63% $2.10* 19.4K Dec 2, 2022 Direct F1
transaction TRDA Common Stock Sale -$52.9K -2.91K -14.99% $18.20 16.5K Dec 2, 2022 Direct F1, F2
transaction TRDA Common Stock Options Exercise $420 +200 +1.21% $2.10* 16.7K Dec 5, 2022 Direct F1
transaction TRDA Common Stock Sale -$3.61K -200 -1.2% $18.05 16.5K Dec 5, 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRDA Stock Option (Right to Buy) Options Exercise $0 -2.91K -2.68% $0.00 106K Dec 2, 2022 Common Stock 2.91K $2.10 Direct F1, F4
transaction TRDA Stock Option (Right to Buy) Options Exercise $0 -200 -0.19% $0.00 105K Dec 5, 2022 Common Stock 200 $2.10 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 25% of the shares subject to this option shall vest and become exercisable on November 16, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.